Nimodipine

證據等級: L5

預測適應症: 2 個

Nimodipine: From Cerebral Vasospasm to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Nimodipine is a dihydropyridine-class L-type voltage-gated calcium channel (VGCC) blocker with selective affinity for cerebral vasculature, established in clinical practice for the prevention of ischemic neurological deficits following subarachnoid hemorrhage. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia (HoFH), however no clinical trials or supporting publications have been identified for this indication, and the mechanistic rationale is assessed as highly speculative.

Quick Overview

Item	Content
Original Indication	Cerebral vasospasm / prevention of ischemic deficits after subarachnoid hemorrhage (globally established; not registered in the Philippines)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.29%
Evidence Level	L5
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacological knowledge, Nimodipine belongs to the dihydropyridine class of calcium channel blockers and selectively inhibits L-type voltage-gated calcium channels (VGCC) in cerebrovascular smooth muscle, reducing cerebral arterial vasospasm without substantial systemic hemodynamic effects.

HoFH is a severe monogenic disorder caused by homozygous loss-of-function mutations in the LDL receptor (LDLR) gene, resulting in profoundly elevated LDL-C (often >13 mmol/L) and accelerated premature atherosclerosis. The primary deficit is at the receptor level: absent or dysfunctional LDLR prevents hepatic clearance of LDL particles. Nimodipine’s mechanism — blockade of sarcolemmal calcium influx — has no direct interface with the LDLR pathway, LDL particle metabolism, or cholesterol biosynthesis.

The repurposing rationale generated by the system acknowledges this gap: the only putative indirect links are (1) in vitro observations that calcium channel blockers may reduce oxidative stress in vascular smooth muscle cells with secondary effects on LDLR expression, and (2) speculative crosstalk between calcium signaling and cholesterol-synthesizing enzymes. Neither has been tested clinically. The high TxGNN score (0.993) is likely attributable to topological proximity in the knowledge graph — multi-hop connections between the HoFH disease node and calcium-signaling nodes — rather than true pharmacological relevance. This prediction is considered a probable knowledge-graph false positive.

Clinical Trial Evidence

Currently no related clinical trials registered for Nimodipine in homozygous familial hypercholesterolemia.

Literature Evidence

Currently no related literature available for Nimodipine in homozygous familial hypercholesterolemia.

Philippines Market Information

Nimodipine is not currently registered with the FDA Philippines. No marketing authorizations are on record.

Safety Considerations

Please refer to the package insert for safety information.

Note for reviewers: Key warnings, contraindications, and drug-drug interaction data were not retrieved in this evidence pack run. Before any further evaluation, the Philippines FDA (or originator SmPC/US prescribing information) should be consulted. Clinically important known safety signals for nimodipine include hypotension, interactions with other antihypertensives and CYP3A4 inhibitors, and IV formulation errors (historical fatalities from inadvertent IV administration of oral solution).

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical or preclinical evidence connecting nimodipine to HoFH, and the mechanistic link is not biologically plausible at the therapeutic target level. The TxGNN score likely reflects knowledge-graph topology rather than pharmacological signal, and the drug is not registered in the Philippines, providing no regulatory starting point.

To proceed, the following would be needed:

Identification of a credible mechanistic hypothesis (e.g., published in vitro or animal data showing a calcium-channel-dependent effect on LDLR expression or LDL-C levels) — none currently exists
At minimum one Phase 2 clinical signal or published case series before this candidate can advance beyond L5
Philippines FDA registration (or a regulatory pathway strategy) before any local development activity
Full safety data retrieval: Philippines FDA product information, SmPC key warnings, contraindications, and DDI profile (CYP3A4 interactions are particularly relevant for this drug class)
Clarification of whether the TxGNN KG topology false-positive flag should trigger automatic deprioritization per pipeline scoring rules
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.